INNERSCOPE HEARING TECHNOLOGIES, INC.

INND | $0.0002 33.33% 4.3M

(0.0% 1d) (50.0% 1m) (-89.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-9.9% volume)
Earnings Calendar:
Market Cap: $ 2,707,901

Sec Filling | Patents | 19 employees

innerscope hearing technologies, inc. (innd) is a nevada corporation incorporated in june 2012, with its principal place of business in roseville, california. innerscope hearing technologies (innd) is a technology driven company with highly scalable b2b and b2c solutions. the company offers a b2b saas based patient management system (pms) software program. in addition to improving operations and communication with patients, innd will also provide a buying group experience for the audiology practice enabling owners to lower product costs and increase their margins. innd will compete in the dtc (direct-to-consumer) markets, - “hearable”, “wearable”, personal sound amplification product (psap). this will also include revolutionary apps on the ios and android markets that will be solely dedicated to the hearing impairment population around the world. a huge untapped market was created estimated to be more than 30 million people in the us alone for (otc) hearing aids as a result of recently

communication

add to watch list Paper trade email alert is off

Ambrx Biopharma Inc - ADR

AMAM 4 | $28.0 0.0% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (187.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (117.58% volume)
Earnings Calendar:
Market Cap: $ 1,768,206,832
https://ambrx.com
Sec Filling | Patents | n/a employees

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.

urea antibody genetic cardiovascular optical metabolic

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-81.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

Convey Holding Parent Inc

CNVY 4 | $10.51 0.0%

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.5% 3d) (0.0% 7d) (239.48% volume)
Earnings Calendar:
Market Cap: $ 769,270,737
https://www.conveyhealthsolutions.com
Sec Filling | Patents | 3000 employees

Convey is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey's administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey's clients include some of the nation's leading health insurance plans and pharmacy benefit management firms. Convey's healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

optical ycombinator

add to watch list Paper trade email alert is off

E-Home Household Service Holdings Ltd

EJH | $2.91 -1.69% -1.72% 4.1M

Professional, Scientific, and T...

(0.0% 1d) (122.6% 1m) (722.2% 1y) (0.0% 2d) (-2.0% 3d) (-5.4% 7d) (-57.11% volume)
Earnings Calendar:
Market Cap: $ 399,153,156

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

IonQ Inc

IONQ 4 | $8.2 2.89% -0.37% 5.9M

Professional, Scientific, and T...

(0.0% 1d) (-16.5% 1m) (44.6% 1y) (0.0% 2d) (6.4% 3d) (12.4% 7d) (9.27% volume)
Earnings Calendar:
Market Cap: $ 1,707,482,056
https://ionq.com
Sec Filling | Patents | n/a employees

IonQ, Inc. is a leader in quantum computing, with a proven track record of innovation and deployment. IonQ’s next-generation quantum computer is the world’s most powerful trapped-ion quantum computer, and IonQ has defined what it believes is the best path forward to scale. IonQ is the only company with its quantum systems available through the cloud on Amazon Braket, Microsoft Azure, and Google Cloud, as well as through direct API access. IonQ was founded in 2015 by Christopher Monroe and Jungsang Kim based on 25 years of pioneering research.

computational

add to watch list Paper trade email alert is off

Quoin Pharmaceuticals Ltd - ADR

QNRX | $0.633 -4.09% -4.27% 55K

Professional, Scientific, and T...

(0.0% 1d) (-22.4% 1m) (-99.1% 1y) (0.0% 2d) (0.0% 3d) (-7.0% 7d) (-37.98% volume)
Earnings Calendar:
Market Cap: $ 2,333,219
https://cellect.co
Sec Filling | Patents | 2020 employees

(IL) Cellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

ceiling t-cell

add to watch list Paper trade email alert is off

Medicine Man Technologies, Inc.

SHWZ | $0.68 -23.21% 9.4K

Professional, Scientific, and T...

(0.0% 1d) (-27.4% 1m) (-38.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-78.68% volume)
Earnings Calendar:
Market Cap: $ 31,530,414

Sec Filling | Patents | 258 employees

medicine man technologies, (symbol: mdcl), offers full service cannabis consulting and licensing of our state-of-the-art, turnkey cultivation and dispensary operating solutions. we represent and license the cultivation and dispensary ip of medicine man, a prominent tier iii colorado operator. we help clients navigate state applications, facility design, business and financial planning, as well as facilitate the adoption of operating procedures and training materials to teach your organization how to effectively operate a commercial cultivation and retail dispensary. we provide the experience and expertise to clients who have the resources necessary to enter the competitive medical and adult use cannabis marketplace, helping to mitigate the costly mistakes that many new companies will experience.

add to watch list Paper trade email alert is off

Entrada Therapeutics Inc

TRDA | $12.54 -2.72% -2.79% 39K

Professional, Scientific, and T...

(0.0% 1d) (-3.7% 1m) (-1.1% 1y) (0.0% 2d) (-1.6% 3d) (6.1% 7d) (-63.07% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 421,357,832

Sec Filling | Patents | 2021 employees

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.729 0.47% 0.47% 20K

Professional, Scientific, and T...

(0.0% 1d) (-27.7% 1m) (30.4% 1y) (0.0% 2d) (5.8% 3d) (5.8% 7d) (-58.52% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 5,005,931
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off